title: Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.
authors.affiliation: Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan. ykobayasi@aichi-cc.jp
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Sakao
authors.forename: Simon
authors.initials: S
authors.lastname: Ito
authors.forename: Jangchul
authors.initials: J
authors.lastname: Park
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kuroda
authors.forename: Noriaki
authors.initials: N
authors.lastname: Sakakura
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Usami
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mitsudomi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yatabe
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D002471:Cell Transformation, Neoplastic; D000077547:Crizotinib; D019008:Drug Resistance, Neoplasm; D058750:Epithelial-Mesenchymal Transition; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D012509:Sarcoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases